医学
福克斯
福尔菲里
伊立替康
化疗
腹泻
结直肠癌
中医药
汤剂
内科学
奥沙利铂
癌症
药理学
胃肠病学
肿瘤科
病理
替代医学
作者
Yau-Tuen Chan,Fan Cheung,Cheng Zhang,Bowen Fu,Hor‐Yue Tan,Hisayoshi Norimoto,Ning Wang,Yibin Feng
标识
DOI:10.3389/fphar.2020.00252
摘要
HLJDD exhibited consistency in quality and stability after 24-month storage. Pre-treatment of HLJDD, but not co-treatment or post-treatment, could significantly improve the diarrhea score, body weight loss and intestinal damage in 5-Fu- and CPT-11-treated mice. Pre-treatment of HLJDD reduced cell apoptosis in the intestine of chemotherapy-treated mice, and promoted renewal of intestinal cell wall. CD44 was predicted as the potential target of HLJDD-containing compounds in CID. HLJDD pre-treatment induced presentation of CD44-postive cells in the intestine of chemotherapy-treated mice, and initiated expression of stemness-associated genes. Transcriptional products of the downstream Wnt signaling of CD44 were elevated. Furthermore, pre-treatment of HLJDD could significantly improve the tumor response of clinical chemotherapy regimens FOLFOX and FOLFIRI in orthotopic colorectal cancer, and reduce diarrhea and intestinal damage. Conclusion: Our study suggests the potential of HLJDD as a neoadjuvant treatment of chemotherapy by reducing diarrhea and improving tumor response.
科研通智能强力驱动
Strongly Powered by AbleSci AI